

Pfizer Research Grant RFP

Research on MBL producing Enterobacterales and/or *Stenotrophomonas maltophilia*

Competitive Grant Program – using Internal Review Panel



Overview

This competitive program aims to study the epidemiological, clinical, economical, and humanistic burden of Metallo-beta lactamases (MBL) producing Enterobacterales and/or *Stenotrophomonas maltophilia* infections including the impact of colonisation.



Geographic Scope

UK, Germany, Austria, Spain, Italy, France, Greece, India, Taiwan, Saudi Arabia, Turkey, Brazil, Mexico, China



Project Types and Area of Interest

Research focused on the following areas concerning

MBL producing Enterobacterales and/or *Stenotrophomonas maltophilia* infections in adults in healthcare settings.

- The epidemiology of MBL producing pathogens amongst Enterobacterales and *Stenotrophomonas maltophilia*, including but not limited to the details on the variants of MBLs (eg. NDM 1, NDM-5, VIM, IMP), site of infection, source (community or hospital acquired)
- The clinical impact of these infections- severity, morbidity, mortality
- Patient risk factors associated with MBL infections
- Association of colonisation and infection in patients
- Cumulative analysis of the effectiveness, safety, type of therapy (empiric/targeted), susceptibility testing, challenges with current therapies like administration errors, varied dosing patterns for combination therapies)
- The economic impact- Healthcare resource utilization, LoS, direct and indirect costs
- The humanistic impact- on patient Quality of Life (QoL)



Key Milestones

- Application submission deadline: **August 8th, 2024**
- Anticipated decision notification date: **October 2024**
- Anticipated project start date: **on or after December 20th, 2024**



Funding Range and Project Length

Individual projects requesting up to \$75,000 USD will be considered. Pfizer anticipates awarding 2-4 projects in total.

I. Eligibility

Geographic Scope:

- UK, Germany, Austria, Spain, Italy, France, Greece, India, Taiwan, Saudi Arabia, Turkey, Brazil, Mexico, China

Applicant Eligibility Criteria

- The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), or an advanced degree in Pharmacy.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI's research coordinator).
- The PI must be an employee or independent contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

II. Requirements

Date RFP Issued

- June 24, 2024

Clinical Area

- MBL producing Enterobacterales and *Stenotrophomonas maltophilia*

Specific Area of Interest for this RFP:

- The intent of this Request for Proposal (RFP) is to study epidemiological, clinical, economic, and humanistic burden of infections (and colonisation) by MBL producing Enterobacterales and study epidemiological, clinical, economic, and humanistic burden of infections due to *Stenotrophomonas maltophilia*.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$75,000 USD will be considered. Pfizer anticipates awarding 2-4 projects in total.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel's evaluation of the proposal and costs involved and will be stated clearly in the grant agreement.
- **Note: grant requests for drug/compound are not in scope of this RFP.**

Key Dates:

- RFP Release Date: **June 24, 2024**
- Grant Application due date: **August 8, 2024**
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: **October 2024**
- Grants will be distributed following a fully executed agreement and submission of Final Protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption or waiver.

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. *[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]*
- Click the "Start a New Research Grant Application" button.
- In the application:
 - For the question “Competitive Grant?” select Yes
 - Select the following Competitive Grant Program Name: 2024 HOS Global ATM-AVI RES
 - Select the following Primary Area of Interest: Infectious Disease – Bacterial- RES
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Camille Jimenez (camille.jimenez@pfizer.com), with the subject line “2024 HOS Global ATM-AVI RES.”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References

- Mojica MF, Papp-Wallace KM, Taracila MA, Barnes MD, Rutter JD, Jacobs MR, et al. Avibactam restores the susceptibility of clinical isolates of *Stenotrophomonas maltophilia* to aztreonam. *Antimicrob Agents Chemother*. 2017;61(10).
- Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against metallo- β -Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020. *J Glob Antimicrob Resist*. 2024; 36:123-31.
- Boyd SE, et al. *Antimicrob Agents Chemother* 2020;64:e00397-20
- Falcone M, et al. *Clin Infect Dis* 2021;72:1871–78.
- Timsit JF, et al. *Antibiotics (Basel)* 2022;11:144
- Nami Morales-Durán, Angel León-Buitimea, José R. Morones-Ramírez, Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions, *Heliyon*, Volume 10, Issue 6, 2024, e27984, ISSN 2405-8440, <https://doi.org/10.1016/j.heliyon.2024.e27984>.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.

Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.

Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.
 - An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

Budget Detail

- The budget amount requested must be in U.S. dollars (USD).
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.